$TECX
Tectonic Therapeutic, Inc.

2021 Q2 Form 10-Q Financial Statement

#000156459021041725 Filed on August 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2021 Q1 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.831M $8.360M $7.990M
YoY Change 10.53% 0.48% 83.68%
% of Gross Profit
Research & Development $22.54M $18.53M $20.87M
YoY Change 8.02% 1.42% 70.13%
% of Gross Profit
Depreciation & Amortization $299.0K $291.0K $301.0K
YoY Change -0.66% 2.83% 50.5%
% of Gross Profit
Operating Expenses $31.38M $26.88M $28.86M
YoY Change 8.71% 1.11% 73.73%
Operating Profit -$26.88M
YoY Change 1.11%
Interest Expense -$12.00K -$20.00K $30.00K
YoY Change -140.0% -103.23% -94.64%
% of Operating Profit
Other Income/Expense, Net -$15.00K
YoY Change -102.44%
Pretax Income -$31.39M -$26.90M -$28.83M
YoY Change 8.87% 3.58% 79.51%
Income Tax
% Of Pretax Income
Net Earnings -$31.39M -$26.90M -$28.83M
YoY Change 8.88% 3.57% 79.56%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$738.3K -$646.3K -$798.6K
COMMON SHARES
Basic Shares Outstanding 41.62M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q2 2021 Q1 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $226.4M $233.0M $244.4M
YoY Change -7.35% -9.58% 170.65%
Cash & Equivalents $226.4M $233.0M $244.4M
Short-Term Investments
Other Short-Term Assets $516.0K $387.0K $997.0K
YoY Change -48.24% -59.94% 203.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $233.5M $242.1M $251.0M
YoY Change -6.96% -8.74% 155.63%
LONG-TERM ASSETS
Property, Plant & Equipment $3.990M $2.930M $3.580M
YoY Change 11.45% -13.82% 30.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $586.0K $900.0K $1.000M
YoY Change -41.4% -10.0% -5.66%
Total Long-Term Assets $4.576M $3.800M $4.600M
YoY Change -0.52% -13.64% 21.02%
TOTAL ASSETS
Total Short-Term Assets $233.5M $242.1M $251.0M
Total Long-Term Assets $4.576M $3.800M $4.600M
Total Assets $238.1M $245.9M $255.6M
YoY Change -6.85% -8.82% 150.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.029M $2.700M $2.600M
YoY Change -21.96% 28.57% 1.09%
Accrued Expenses $14.67M $9.822M $12.79M
YoY Change 14.64% 416.95% 106.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.95M $12.80M $15.40M
YoY Change 10.08% 0.0% 75.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $150.0K $200.0K $400.0K
YoY Change -62.5% -50.0% -33.33%
Total Long-Term Liabilities $150.0K $200.0K $400.0K
YoY Change -62.5% -50.0% -33.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.95M $12.80M $15.40M
Total Long-Term Liabilities $150.0K $200.0K $400.0K
Total Liabilities $17.10M $13.00M $15.80M
YoY Change 8.25% -1.52% 68.89%
SHAREHOLDERS EQUITY
Retained Earnings -$322.7M -$291.3M -$199.5M
YoY Change 61.75% 90.19%
Common Stock $439.3M
YoY Change 122.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $221.0M $232.9M $239.8M
YoY Change
Total Liabilities & Shareholders Equity $238.1M $245.9M $255.6M
YoY Change -6.84% -8.82% 150.58%

Cashflow Statement

Concept 2021 Q2 2021 Q1 2020 Q2
OPERATING ACTIVITIES
Net Income -$31.39M -$26.90M -$28.83M
YoY Change 8.88% 3.57% 79.56%
Depreciation, Depletion And Amortization $299.0K $291.0K $301.0K
YoY Change -0.66% 2.83% 50.5%
Cash From Operating Activities -$19.96M -$27.34M -$21.02M
YoY Change -5.02% 21.86% 17.04%
INVESTING ACTIVITIES
Capital Expenditures -$1.224M $115.0K -$490.0K
YoY Change 149.8% -80.07% 22.5%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.224M -$115.0K -$490.0K
YoY Change 149.8% -80.07% 22.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.60M 799.0K 8.190M
YoY Change 78.32% -99.15% 3312.5%
NET CHANGE
Cash From Operating Activities -19.96M -27.34M -21.02M
Cash From Investing Activities -1.224M -115.0K -490.0K
Cash From Financing Activities 14.60M 799.0K 8.190M
Net Change In Cash -6.584M -26.66M -13.32M
YoY Change -50.57% -137.73% -26.49%
FREE CASH FLOW
Cash From Operating Activities -$19.96M -$27.34M -$21.02M
Capital Expenditures -$1.224M $115.0K -$490.0K
Free Cash Flow -$18.74M -$27.45M -$20.53M
YoY Change -8.72% 19.31% 16.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M9D
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6721000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
96000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
186013000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
232930000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4691000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
208000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-31387000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
220992000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
187535000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
254344000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9326000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
850000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
208000
us-gaap Net Income Loss
NetIncomeLoss
-58286000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
220992000
us-gaap Profit Loss
ProfitLoss
-58286000
us-gaap Profit Loss
ProfitLoss
-54801000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
589000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
584000
us-gaap Share Based Compensation
ShareBasedCompensation
9326000
us-gaap Share Based Compensation
ShareBasedCompensation
6721000
avro Deferred Rent Expense
DeferredRentExpense
-106000
avro Deferred Rent Expense
DeferredRentExpense
-108000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-478000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1987000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-343000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-76000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-653000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-930000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1005000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3019000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47304000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43452000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1344000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1065000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1344000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1065000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
850000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
96000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
204000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15404000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
101854000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33244000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
57337000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
260174000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
226930000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
244872000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
171000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
226438000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
244380000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
492000
CY2020Q2 us-gaap Restricted Cash
RestrictedCash
492000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of the Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AVROBIO, Inc. (the “Company” or “AVROBIO”) is a clinical-stage gene therapy company focused on developing potentially curative <span style="font-style:italic;">ex vivo</span> lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to clinical-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. <span style="font-size:12pt;">              </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred recurring losses since its inception, including net losses of <span>$58,286<span style="font-size:12pt;"> </span></span>and $54,801 for the six months ended June 30, 2021 and 2020, respectively. In addition, as of June 30, 2021, the Company had an accumulated deficit of $322,702. The Company has primarily funded these losses through the proceeds from sales of common and preferred stock. Although the Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects that its existing cash and cash equivalents on hand as of June 30, 2021 of $226,438 will be sufficient to fund current planned operations and capital expenditure requirements for at least the next twelve months from the filing date of this Quarterly Report on Form 10-Q with the Securities and Exchange Commission (“SEC”). However, the future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.<span style="font-size:12pt;">   </span></p>
us-gaap Net Income Loss
NetIncomeLoss
-58286000
us-gaap Net Income Loss
NetIncomeLoss
-54801000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-322702000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
226438000
CY2020Q2 avro Collaborative Agreement Expenses
CollaborativeAgreementExpenses
0
avro Collaborative Agreement Expenses
CollaborativeAgreementExpenses
825000
CY2021Q2 avro Collaborative Agreement Expenses
CollaborativeAgreementExpenses
825000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities and expenses and the related disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant estimates relied upon in preparing the unaudited condensed consolidated financial statements include the determination of the fair value of share-based awards issued and the estimation of accrued research and development expenses. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p>
avro Collaborative Agreement Expenses
CollaborativeAgreementExpenses
0
CY2021Q2 avro Fair Value Input Amount Transfer Between Levels
FairValueInputAmountTransferBetweenLevels
0
CY2021Q2 avro Tax Incentive Refund Current
TaxIncentiveRefundCurrent
2332000
CY2020Q4 avro Tax Incentive Refund Current
TaxIncentiveRefundCurrent
2558000
CY2021Q2 avro Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
3492000
CY2020Q4 avro Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
3145000
CY2021Q2 us-gaap Prepaid Insurance
PrepaidInsurance
39000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
973000
CY2021Q2 avro Prepaid Compensation Benefits
PrepaidCompensationBenefits
702000
CY2020Q4 avro Prepaid Compensation Benefits
PrepaidCompensationBenefits
609000
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
516000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
275000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7081000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7560000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7001000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5485000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3011000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2421000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3990000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3064000
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
299000
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
301000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
589000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
584000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
492000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
492000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5084000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6402000
CY2021Q2 avro Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
8491000
CY2020Q4 avro Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5847000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
897000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1096000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
193000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
348000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14665000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13693000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 avro Undesignated Preferred Stock
UndesignatedPreferredStock
10000000
CY2020Q4 avro Undesignated Preferred Stock
UndesignatedPreferredStock
10000000
CY2021Q2 avro Undesignated Shares Of Preferred Stock Outstanding
UndesignatedSharesOfPreferredStockOutstanding
0
CY2020Q4 avro Undesignated Shares Of Preferred Stock Outstanding
UndesignatedSharesOfPreferredStockOutstanding
0
us-gaap Dividends Cash
DividendsCash
0
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14119884
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12266171
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
21000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0076
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0088
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8125
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7572
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5559545
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.97
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13511000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3743232
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.52
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
196872
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.32
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
693083
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
17.28
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8412822
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.40
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5974000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2622442
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.36
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5575000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1729000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
546000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.16
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
4000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4691000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3899000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9326000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6721000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
62167000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M17D

Files In Submission

Name View Source Status
0001564590-21-041725-index-headers.html Edgar Link pending
0001564590-21-041725-index.html Edgar Link pending
0001564590-21-041725.txt Edgar Link pending
0001564590-21-041725-xbrl.zip Edgar Link pending
avro-10q_20210630.htm Edgar Link pending
avro-10q_20210630_htm.xml Edgar Link completed
avro-20210630.xsd Edgar Link pending
avro-20210630_cal.xml Edgar Link unprocessable
avro-20210630_def.xml Edgar Link unprocessable
avro-20210630_lab.xml Edgar Link unprocessable
avro-20210630_pre.xml Edgar Link unprocessable
avro-ex311_13.htm Edgar Link pending
avro-ex312_12.htm Edgar Link pending
avro-ex321_14.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending